Cited by 774Heat shock proteins researchHistone Deacetylase Inhibitors ResearchUbiquitin and proteasome pathways

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Open access

Bali, Purva, Pranpat, Michael, Bradner, James, Balasis, Maria, Fiskus, Warren, Guo, Fei, Rocha, Kathy, Kumaraswamy, Sandhya, Boyapalle, Sandhya, Atadja, Peter, Seto, Edward, Bhalla, Kapil·2005·Journal of Biological Chemistry

DOI 10.1074/jbc.c500186200

Open this paper in CoChat — free account

Abstract

The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90. This promotes the polyubiquitylation and degradation of the pro-growth and pro-survival client proteins Bcr-Abl, mutant FLT-3, c-Raf, and AKT in human leukemia cells. HDAC6 is a member of the class IIB HDACs. It is predominantly cytosolic, microtubule-associated alpha-tubulin deacetylase that is also known to promote aggresome inclusion of the misfolded polyubiquitylated proteins. Here we demonstrate that in the Bcr-abl oncogene expressing human leukemia K562 cells, HDAC6 can be co-immunoprecipitated with HSP90, and the knock-down of HDAC6 by its siRNA induced the acetylation of HSP90 and alpha-tubulin. Depletion of HDAC6 levels also inhibited the binding of HSP90 to ATP, reduced the chaperone association of HSP90 with its client proteins, e.g. Bcr-Abl, and induced polyubiquitylation and partial depletion of Bcr-Abl. Conversely, the ectopic overexpression of HDAC6 inhibited LAQ824-induced acetylation of HSP90 and alpha-tubulin and reduced LAQ824-mediated depletion of Bcr-Abl, AKT, and c-Raf. Collectively, these findings indicate that HDAC6 is also an HSP90 deacetylase. Targeted inhibition of HDAC6 leads to acetylation of HSP90 and disruption of its chaperone function, resulting in polyubiquitylation and depletion of pro-growth and pro-survival HSP90 client proteins including Bcr-Abl. Depletion of HDAC6 sensitized human leukemia cells to HAA-HDIs and proteasome inhibitors.

Integrity signals

Registry

Crossref · 10.1074/jbc.c500186200

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein
Hartl, F. U., & Hayer-Hartl, M. K. (2002) · Science · doi:10.1126/science.1068408 · Cited by 3,335
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress
Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529
Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,497
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent
Stebbins, C. E., Russo, A. A., Schneider, C. B., Rosen, N. X., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,370
Controlling the double helix
Felsenfeld, G., & Groudine, M. T. (2003) · Nature · doi:10.1038/nature01411 · Cited by 1,252
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,052
Heat-shock protein 90, a chaperone for folding and regulation
Picard, D. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012491 · Cited by 812

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 5

Nimmanapalli, 2001, Cancer Res., 61, 1799
Nimmanapalli, 2003, Cancer Res., 63, 5126
Fuino, 2003, Mol. Cancer Ther., 2, 971
Nimmanapalli, 2002, Cancer Res., 62, 5761
Bagatell, 2000, Clin. Cancer Res., 6, 3312

Sorted by citations

Items 301–400 of 774

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention
Alseksek, R. K., Ramadan, W. S. H., Saleh, E., & El‐Awady, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158141 · Cited by 59
Preclinical anti‐myeloma activity of the novel HDAC‐inhibitor JNJ‐26481585
Stühmer, T., Arts, J., Chatterjee, M., Borawski, J. M., Wolff, A., King, P., Einsele, H., Leo, E., & Bargou, R. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08126.x · Cited by 55
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients
Lv, Z., Weng, X., Du, C., Zhang, C., Xiao, H., Cai, X., Ye, S., Cheng, J., Ding, C., Xie, H., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22345 · Cited by 55
FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70
Wang, Y., Wang, S., Zhang, X., Zhao, M., Hou, C., Xu, Y.-J., Du, Z., & Yu, X. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.076 · Cited by 55
Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
To, K. K. W., Robey, R. W., Zhan, Z., Bangiolo, L., & Bates, S. E. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0270 · Cited by 56
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
Soverini, S., Iacobucci, I., Baccarani, M., & Martinelli, G. (2007) · Haematologica · doi:10.3324/haematol.11248 · Cited by 53
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
Thomas, S., & Münster, P. N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.026 · Cited by 56
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Putcha, P., Yu, J., Barrueco, R. R., Saucedo-Cuevas, L. P., Villagrasa, P., Murga-Penas, E., Quayle, S. N., Yang, M., Castro, V., Llobet‐Navàs, D., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0658-0 · Cited by 55
MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors
Gold, W. A., Lacina, T. A., Cantrill, L. C., & Christodoulou, J. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1202-x · Cited by 53
The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation
Chuang, M., Wu, S.-T., Tang, S., Lai, X., Lai, H.-C., Hsu, K.-H., Sun, K., Sun, G.-H., Chang, S.-Y., Yü, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073401 · Cited by 54
Histone Deacetylase 10 Relieves Repression on the Melanogenic Program by Maintaining the Deacetylation Status of Repressors
Lai, I., Lin, T.-P., Yao, Y., Lin, C., Hsieh, M.-J., & Yang, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.061861 · Cited by 54
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Špıčka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S. D., Jagannath, S., & Anderson, K. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.006 · Cited by 55
Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach
Hsu, K., Liu, C., Lin, T. E., Hsieh, J.-H., Sung, T.-Y., Tseng, H.-J., Yang, J., & Huang, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-03417-1 · Cited by 54
Heat Shock Protein 90: A Unique Chemotherapeutic Target
Cullinan, S. B., & Whitesell, L. J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.001 · Cited by 55
LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway
Hasegawa, H., Yamada, Y., Tsukasaki, K., Mori, N., Tsuruda, K., Sasaki, D., Usui, T., Osaka, A., Atogami, S., Ishikawa, C., et al. (2011) · Leukemia · doi:10.1038/leu.2010.315 · Cited by 58
Histone deacetylase 6 gates the synaptic action of acute stress in prefrontal cortex
Lee, J. B., Wei, J., Liu, W., Cheng, J., Feng, J., & Yan, Z. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.224907 · Cited by 52
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists
Mandawat, A., Fiskus, W. C., Buckley, K. M., Robbins, K. R., Rao, R., Balusu, R., Navenot, J.-M., Wang, Z., Üstün, C., Chong, D. G., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284414 · Cited by 53
Self-citation
Alternative Approaches to Hsp90 Modulation for the Treatment of Cancer
Hall, J. A., Forsberg, L. K., & Blagg, B. S. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.89 · Cited by 52
Class I and IIa HDACs Mediate HIF-1α Stability Through PHD2-Dependent Mechanism, While HDAC6, a Class IIb Member, Promotes HIF-1α Transcriptional Activity in Nucleus Pulposus Cells of the Intervertebral Disc
Schoepflin, Z. R., Shapiro, I. M., & Risbud, M. V. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2787 · Cited by 53
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091883 · Cited by 54
Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy
Lee, H. B., Noh, H., Seo, J. Y., Yu, M. R., & Ha, H. (2007) · Kidney International · doi:10.1038/sj.ki.5002388 · Cited by 52
Role of Epigenetics in Chronic Myeloid Leukemia
Poláková, K. M., Koblihova, J., & Stopka, T. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0152-z · Cited by 52
Post-translational modification of heat-shock protein 90: impact on chaperone function
Scroggins, B. T., & Neckers, L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.10.1403 · Cited by 52
HDAC6: Physiological function and its selective inhibitors for cancer treatment
Yang, P. (2013) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2013.v7.6.233 · Cited by 56
Epigenetics and autosomal dominant polycystic kidney disease
Li, X. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.008 · Cited by 53
Mitochondrial Acetylation and Diseases of Aging
Wagner, G. R., & Payne, R. M. (2011) · Journal of Aging Research · doi:10.4061/2011/234875 · Cited by 52
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Stahl, M. F., Gore, S. D., Vey, N., & Prébet, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1146251 · Cited by 52
Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis
Dahabieh, M. S., Ha, Z., Pietro, E. D., Nichol, J. N., Bolt, A. M., Gonçalves, C., Dupéré-Richer, D., Pettersson, F., Mann, K. K., Braverman, N., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.115 · Cited by 52
Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect
Messaoudi, K., Ali, A., Ishaq, R., Palazzo, A., Sliwa, D., Bluteau, O., Souquère, S., Muller, D., Diop, M. K., Rameau, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01690-2 · Cited by 52
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase
Park, J., Jong, H.-S., Kim, S. G., Jung, Y., Lee, K., Lee, J., Kim, D., Bang, Y., & Kim, T. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0260-8 · Cited by 52
HDACi - going through the mechanisms
Wańczyk, M. (2010) · Frontiers in bioscience · doi:10.2741/3691 · Cited by 51
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Park, H., Garrido‐Laguna, I., Naing, A., Fu, S., Falchook, G. S., Piha-Paul, S. A., Wheler, J. J., Hong, D. S., Tsimberidou, A. M., Subbiah, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11750 · Cited by 51
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
Lu, D., Yan, J., Wang, L., Liu, H., Zeng, L., Zhang, M., Duan, W., Ji, Y., Cao, J., Geng, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00172 · Cited by 50
Givinostat: an emerging treatment for polycythemia vera
Chifotides, H. T., Bose, P., & Verstovšek, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1761323 · Cited by 51
Hsp90: From Cellular to Organismal Proteostasis
Somogyvári, M., Khatatneh, S., & Sőti, C. (2022) · Cells · doi:10.3390/cells11162479 · Cited by 55
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
Xu, X., Xie, C., Edwards, H. J., Zhou, H., Buck, S. A., & Ge, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017138 · Cited by 50
Degradation of HIF-1alpha under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy
Barliya, T., Mandel, M., Livnat, T., Weinberger, D., & Lavie, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022849 · Cited by 50
Targeting histone deacetylases for the treatment of disease
Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00571.x · Cited by 49
Exploiting cellular pathways to develop new treatment strategies for AML
Fathi, A. T., Grant, S., & Karp, J. E. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.004 · Cited by 50
Histone deacetylase inhibitor‐mediated cell death is distinct from its global effect on chromatin
Luchenko, V. L., Litman, T., Chakraborty, A. R., Heffner, A., Devor, C. B., Wilkerson, J., Stein, W. D., Robey, R. W., Bangiolo, L., Levens, D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.001 · Cited by 50
Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells
Rao, R., Nalluri, S., Fiskus, W. C., Savoie, A., Buckley, K. M., Ha, K., Balusu, R., Joshi, A., Coothankandaswamy, V., Tao, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0529 · Cited by 50
Self-citation
Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin
Oya, Y., Mondal, A., Rawangkan, A., Umsumarng, S., Iida, K., Watanabe, T., Kanno, M., Suzuki, K., Li, Z., Kagechika, H., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.12.015 · Cited by 51
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells
Rosik, L., Niegisch, G., Fischer, U., Jung, M., Schulz, W. A., & Hoffmann, M. J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28469 · Cited by 47
A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax ® )
Harrison, S. J., Bishton, M. J., Bates, S. E., Grant, S., Piekarz, R., Johnstone, R. W., Dai, Y., Lee, B., Araujo, M. E., & Prince, H. M. (2012) · Epigenomics · doi:10.2217/epi.12.52 · Cited by 49
DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells
Castro‐Piedras, I., Sharma, M., den Bakker, M., Molehin, D., Martinez, E. G., Vartak, D., Pruitt, W. M., Deitrick, J., Almodóvar, S., & Pruitt, K. (2018) · Oncotarget · doi:10.18632/oncotarget.26257 · Cited by 49
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Okubo, K., Isono, M., Miyai, K., Asano, T., & Sato, A. (2019) · Cancer Science · doi:10.1111/cas.14225 · Cited by 49
Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat
Kahali, S., Sarcar, B., Fang, B., Williams, E. S., Koomen, J. M., Tofilon, P. J., & Chinnaiyan, P. (2010) · Neoplasia · doi:10.1593/neo.91422 · Cited by 49
Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts
Chung, Y., Troy, H., Kristeleit, R. S., Aherne, W., Jackson, L. E., Atadja, P. W., Griffiths, J. R., Judson, I. R., Workman, P., Leach, M. O., et al. (2008) · Neoplasia · doi:10.1593/neo.07834 · Cited by 48
Self-citation
Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90
Meng, Q., Chen, X., Sun, L., Zhao, C., Sui, G., & Cai, L. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0651-y · Cited by 48
mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms
Wilson-Edell, K. A., Yevtushenko, M. A., Rothschild, D. E., Rogers, A. N., & Benz, C. C. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2877-y · Cited by 48
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 49
New HDAC6-mediated deacetylation sites of tubulin in the mouse brain identified by quantitative mass spectrometry
Liu, N., Xiong, Y., Li, S., Ren, Y., He, Q., Gao, S., Zhou, J., & Shui, W. (2015) · Scientific Reports · doi:10.1038/srep16869 · Cited by 48
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Mrakovcic, M., Bohner, L. O. L., Hanisch, M. R., & Fröhlich, L. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123952 · Cited by 50
Therapeutic effects of histone deacetylase inhibitors on kidney disease
Chun, P. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0998-7 · Cited by 48
Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
Itsumi, M., Shiota, M., Takeuchi, A., Kashiwagi, E., Inokuchi, J., Tatsugami, K., Kajioka, S., Uchiumi, T., Naito, S., Eto, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12948 · Cited by 47
Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
Elmallah, M. I. Y., & Micheau, O. (2019) · Cancers · doi:10.3390/cancers11060850 · Cited by 48
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
Lernoux, M., Schnekenburger, M., Losson, H., Vermeulen, K., Hahn, H., Gérard, D., Lee, J., Mazumder, A., Ahamed, M., Christov, C., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00839-z · Cited by 49
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy
Watanabe, T., Nagase, K., Chosa, M., & Tobinai, K. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605954 · Cited by 47
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
Bruserud, Ø., Stapnes, C., Tronstad, K. J., Ryningen, A., Ånensen, N., & Gjertsen, B. T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.51 · Cited by 48
Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
Wang, G., He, J., Zhao, J., Yun, W., Xie, C., Taub, J. W., Azmi, A. S., Mohammad, R. M., Dong, Y., Kong, W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052095 · Cited by 47
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M. L., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C. M., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 46
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias
Bansal, H., Bansal, S., Rao, M. K., Foley, K. P., Sang, J., Proia, D. A., Blackman, R. K., Ying, W., Barsoum, J., Baer, M. R., et al. (2010) · Blood · doi:10.1182/blood-2009-10-247239 · Cited by 46
Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives
Chianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., & Franci, G. (2021) · Cancers · doi:10.3390/cancers13112761 · Cited by 47
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Hassig, C. A., Symons, K. T., Guo, X., Nguyen, P.-M., Annable, T., Wash, P. L., Payne, J. E., Jenkins, D. A., Bonnefous, C., Trotter, C., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2347 · Cited by 44
Epigenetic Treatment of Neurological Disease
Gray, S. G. (2011) · Epigenomics · doi:10.2217/epi.11.67 · Cited by 45
Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
Dedes, K. J., Dedes, I., Imesch, P., von Bueren, A. O., Fink, D. A., & Fedier, A. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283262a32 · Cited by 45
Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
Leone, G. G. M., D’Alò, F., Zardo, G., Voso, M. T., & Nervi, C. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784534947 · Cited by 46
Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
Kaiser, M., Lamottke, B., Mieth, M., Jensen, M. R., Quadt, C., Garcı́a-Echeverrı́a, C., Atadja, P. W., Heider, U., von Metzler, I., Türkmen, S., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01403.x · Cited by 44
Self-citation
Novel therapeutic approaches in chronic myeloid leukemia
Yurttaş, N. Ö., & Eşkazan, A. E. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106337 · Cited by 47
How Influenza Virus Uses Host Cell Pathways during Uncoating
Moreira, É. A., Yamauchi, Y., & Matthias, P. (2021) · Cells · doi:10.3390/cells10071722 · Cited by 44
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas
Jacob, A., Oblinger, J. L., Bush, M. L., Brendel, V. J., Santarelli, G. D., Chaudhury, A. R., Kulp, S. K., Perle, K. M. D. L., Chen, C., Chang, L., et al. (2011) · The Laryngoscope · doi:10.1002/lary.22392 · Cited by 43
Epigenetic therapies in haematological malignancies: Searching for true targets
Altucci, L., & Minucci, S. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.03.001 · Cited by 46
HDAC Inhibitors and Chaperone Function
Rao, R., Fiskus, W. C., Ganguly, S., Kambhampati, S., & Bhalla, K. N. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00007-0 · Cited by 46
Self-citation
The Current State of Charcot–Marie–Tooth Disease Treatment
Okamoto, Y., & Takashima, H. (2023) · Genes · doi:10.3390/genes14071391 · Cited by 43
Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy
Kaufman, J. L., Fabre, C., Lonial, S., & Richardson, P. G. G. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.016 · Cited by 45
Extensive functional redundancy in the regulation of C andida albicans drug resistance and morphogenesis by lysine deacetylases H os2, H da1, R pd3 and R pd31
Li, X., Robbins, N., O’Meara, T. R., & Cowen, L. E. (2016) · Molecular Microbiology · doi:10.1111/mmi.13578 · Cited by 46
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells
Sanda, T., Okamoto, T., Uchida, Y., Nakagawa, H., Iida, S., Kayukawa, S., Suzuki, T., Oshizawa, T., Suzuki, T., Miyata, N., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404902 · Cited by 43
Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function
Joshi, A., Barabutis, N., Birmpas, C., Dimitropoulou, C., Thangjam, G. S., Cherian‐Shaw, M., Dennison, J., & Catravas, J. D. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00180.2015 · Cited by 42
Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response
Kahali, S., Sarcar, B., Prabhu, A. H., Seto, E., & Chinnaiyan, P. (2012) · The FASEB Journal · doi:10.1096/fj.11-193706 · Cited by 42
Self-citation
Hsp90
Jarosz, D. F. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.11.001 · Cited by 41
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
Muscal, J. A., Scorsone, K. A., Zhang, L., Ecsedy, J., & Berg, S. L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9831-9 · Cited by 41
Histone Deacetylase Inhibitors and Rational Combination Therapies
Grant, S., & Dai, Y. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00006-9 · Cited by 42
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 41
Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90
Pinzi, L., Benedetti, R., Altucci, L., & Rastelli, G. (2020) · ACS Omega · doi:10.1021/acsomega.0c00559 · Cited by 42
Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma
Iglesias‐Linares, A., Yáñez-Vico, R.-M., & González‐Moles, M. Á. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.01.009 · Cited by 42
Epigenetic Regulation of Muscle Phenotype and Adaptation: A Potential Role in COPD Muscle Dysfunction
Barreiro, E., & Sznajder, J. I. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01027.2012 · Cited by 47
Targeting mTOR for the treatment of B cell malignancies
Lee, J. S., Vo, T.-T. T., & Fruman, D. A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12888 · Cited by 39
Creating a “Prosurvival Phenotype” Through Histone Deacetylase Inhibition
Halaweish, I. F., Nikolian, V. C., Georgoff, P. E., Li, Y., & Alam, H. B. (2015) · Shock · doi:10.1097/shk.0000000000000319 · Cited by 40
Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
Matsuda, Y., Yamauchi, T., Hosono, N., Uzui, K., Negoro, E., Morinaga, K., Nishi, R., Yoshida, A., Kimura, S. H., Maekawa, T., et al. (2016) · Cancer Science · doi:10.1111/cas.12965 · Cited by 39
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
Kim, I. A., No, M., Lee, J. M., Shin, J. H., Oh, J. S., Choi, E. J., Kim, I. H., Atadja, P. W., & Bernhard, E. J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.03.008 · Cited by 40
Self-citation
Misfolded Proteins: From Little Villains to Little Helpers in the Fight Against Cancer
Brüning, A., & ckstock, J. J. ⁄. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00047 · Cited by 41
Vorinostat and Bortezomib Synergistically Cause Ubiquitinated Protein Accumulation in Prostate Cancer Cells
Sato, A., Asano, T., Ito, K., & Asano, T. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.07.108 · Cited by 39
A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Shanmugam, R., Gade, P., Wilson-Weekes, A., Sayar, H., Suvannasankha, A., Goswami, C. P., Li, L., Gupta, S. K., Cardoso, A. A., Baghdadi, T. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3022 · Cited by 40
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina, G., Marampon, F., Muzi, P., Mancini, A., Piccolella, M., Negri-Cesi, P., Motta, M., Lenzi, A., Cesare, E. D., Tombolini, V., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0240 · Cited by 43
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A
Oral, D., Erkekoğlu, P., Kocer-Gumusel, B., & Chao, M. (2016) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2016014200 · Cited by 39
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
Singh, A., Patel, V. K., Jain, S., Patel, P., & Rajak, H. (2016) · Oncology and Therapy · doi:10.1007/s40487-016-0023-1 · Cited by 43
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
Ding, H., Peterson, K. L., Correia, C., Koh, B. D., Schneider, P., Nowakowski, G. S., & Kaufmann, S. H. (2016) · Leukemia · doi:10.1038/leu.2016.357 · Cited by 40
Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition
You, D., Richardson, J. R., & Aleksunes, L. M. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089953 · Cited by 40
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents
Bishton, M. J., Kenealy, M. K., Johnstone, R. W., Rasheed, W. K., & Prince, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1439 · Cited by 39

Authors: Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E., & Bhalla, K.
Affiliations: Moffitt Cancer Center (US)
Dana-Farber Cancer Institute (US)
Novartis (United States) (US)
Corresponding author: Bhalla, Kapil
ORCID: Bradner, James
Balasis, Maria
Fiskus, Warren
Guo, Fei
Seto, Edward
Bhalla, Kapil
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 2005-07
Volume: 280
Issue: 29
Pages: 26729-26734
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1074/jbc.c500186200
OpenAlex: W2151445954
Cited by: 755
References: 42
Citations by year: 2026: 9 · 2025: 16 · 2024: 10 · 2023: 9 · 2022: 23 · 2021: 21 · 2020: 38 · 2019: 33 · 2018: 32 · 2017: 28 · 2016: 34 · 2015: 40 · 2014: 45 · 2013: 42 · 2012: 47
FWCI: 19.90
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 5555 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: HDAC6, HSP90, HSP90 acetylation, LAQ824, panobinostat, BCR-ABL, alpha-tubulin deacetylation, polyubiquitination, Hsp90 client proteins, Akt, Raf-1, leukemia, K562 cells, proteasome inhibitors, siRNA knockdown
MeSH terms: Histone Deacetylase 6, Panobinostat, Acetylation, Antineoplastic Agents, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Leukemia, Neoplasm Proteins, Protein Binding, Molecular Chaperones, HSP90 Heat-Shock Proteins, K562 Cells, Ubiquitin, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks